Related Experiment Video
Updated: Aug 14, 2026

Murine Kidney Transplant Technique
Published on: October 20, 2015
[7 years' experience with hepatic transplantation in children]
V Martínez Ibañez1, J Iglesias, J Lloret
1Hospital Infantil Vall d'Hebrón, Departamento de Cirugía Pediátrica, Universidad Autónoma de Barcelona.
Insights
Pediatric liver transplantation (LTx) is an effective treatment for end-stage liver diseases in children. Improved therapies and surgical experience have led to satisfactory outcomes and a 70% survival rate.
Area of Science:
- Pediatric Hepatology
- Transplant Surgery
- Clinical Outcomes Research
Context:
- Liver transplantation (LTx) is a critical intervention for pediatric patients with end-stage liver disease.
- This study reviews LTx outcomes in a pediatric cohort over a seven-year period.
- The cohort included diverse etiologies such as cholestatic, metabolic, and miscellaneous liver diseases.
Purpose:
- To evaluate the efficacy and outcomes of liver transplantation in a pediatric population.
- To analyze the complications and survival rates associated with pediatric liver transplantation.
- To assess the impact of evolving therapeutic strategies on patient progress.
Summary:
- A total of 71 liver transplants were performed in 60 pediatric patients (8 months to 14 years) between 1985 and 1991.
- Common indications included cholestatic diseases (62%) and metabolic hepatic-based diseases (25%).
- The study reported complications such as primary non-function (5.5%), severe infections (5.5%), and arterial thrombosis (3%), with an overall actuarial survival rate of 70%.
Impact:
- Pediatric liver transplantation is confirmed as an efficient treatment for end-stage liver diseases.
- Advances in treatment and increased surgical experience have improved patient outcomes.
- The findings support the continued application of LTx in eligible pediatric candidates.
Unlabelled:
Between the 7th of June 1985 and december 1991, 71 liver transplants (LTx) were performed in 60 patients (pts) with ages ranging from 8 months to 14 years and weight between 4 and 38 kg. Sixty-two percent were cholestatic diseases (32 biliary atresia, 3 sclerosing cholangitis and 2 biliary paucity), 25% metabolic hepatic-based diseases (6 glycogen storage disease, 4 Byler disease, 3 tyrosinaemia and 2 alpha-1-antitrypsin deficiency) and 13% miscellaneous diagnosis (2 post-hepatitic cirrhosis, 2 autoimmune hepatitis, 2 fulminant hepatitis and one case of cholesteryl ester storage disease and one case of Budd-Chiari disease). Primary non-function was observed in 4 cases (5.5), severe bacterial infection in 4 pts. (5.5%), severe viral infection in 2 (3%), arterial thrombosis in 2 (3%), arterial rupture in 1 (1.5%), recurrence in 3 cases (5%) and chronic rejection in two (3%). Two patients were in III and IV coma respectively prior to surgery. Intraoperative mortality was nil. Total mortality was 19 cases, which represents an actuarial survival rate of 70%. Our philosophy has always been to offer this treatment to all patients candidates for LTx. In some end-stage situation it is very difficult to objectively assess their possibilities and when necessary refuse the only opportunity the patient has. Nevertheless, results are satisfactory.
In Conclusion:
1. LTx in children has been confirmed in our programme over 7 years as efficient treatment for end-stage liver diseases. 2. Advances in the therapeutic arsenal and increased experience have notably improved the progress of these patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Related Concept Videos
Kidney Transplant I: Introduction
Kidney Transplant II: Surgical Procedure

